Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: Low-dose TBI does not prevent sensitization
Richard A. Nash(Colorado Blood Cancer Institute), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), George E. Georges(Northwestern University), Kraig Abrams(Fred Hutch Cancer Center), Alessandra Takatu(Fred Hutch Cancer Center), German Espino(Fred Hutch Cancer Center), Ziding Feng(The University of Texas MD Anderson Cancer Center), Peter A. McSweeney(Mesoblast (United States)), Sherrill J. Slichter(University of Washington), Howard M. Shulman(Fred Hutch Cancer Center), M. John Gass(Fred Hutch Cancer Center)
Cited by 5
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k